Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Viable tumour-derived epithelial cells (circulating tumour cells or CTCs) have been identified in peripheral blood from cancer patients and are probably the origin of intractable metastatic disease. Although extremely rare, CTCs represent a potential alternative to invasive biopsies as a source of tumour tissue for the detection, characterization and monitoring of non-haematologic cancers. The ability to identify, isolate, propagate and molecularly characterize CTC subpopulations could further the discovery of cancer stem cell biomarkers and expand the understanding of the biology of metastasis. Current strategies for isolating CTCs are limited to complex analytic approaches that generate very low yield and purity. Here we describe the development of a unique microfluidic platform (the 'CTC-chip') capable of efficient and selective separation of viable CTCs from peripheral whole blood samples, mediated by the interaction of target CTCs with antibody (EpCAM)-coated microposts under precisely controlled laminar flow conditions, and without requisite pre-labelling or processing of samples. The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 (99%) samples, with a range of 5-1,281 CTCs per ml and approximately 50% purity. In addition, CTCs were isolated in 7/7 patients with early-stage prostate cancer. Given the high sensitivity and specificity of the CTC-chip, we tested its potential utility in monitoring response to anti-cancer therapy. In a small cohort of patients with metastatic cancer undergoing systemic treatment, temporal changes in CTC numbers correlated reasonably well with the clinical course of disease as measured by standard radiographic methods. Thus, the CTC-chip provides a new and effective tool for accurate identification and measurement of CTCs in patients with cancer. It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer.
Nagrath
Sunitha
S
Surgical Services and BioMEMS Resource Center, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts 02114, USA.
Sequist
Lecia V
LV
Maheswaran
Shyamala
S
Bell
Daphne W
DW
Irimia
Daniel
D
Ulkus
Lindsey
L
Smith
Matthew R
MR
Kwak
Eunice L
EL
Digumarthy
Subba
S
Muzikansky
Alona
A
Ryan
Paula
P
Balis
Ulysses J
UJ
Tompkins
Ronald G
RG
Haber
Daniel A
DA
Toner
Mehmet
M
D002469:Cell Separation / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D046228:Microarray Analysis / Q000295:instrumentation* / Q000379:methods*; D044085:Microfluidics / Q000295:instrumentation / Q000379:methods; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology*; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D012680:Sensitivity and Specificity